Investors
A proven track record of value creation
Our robust business model provides significant opportunities to drive growth and deliver value for investors.
Together we’re building a leading global pharmaceutical business
By putting better health within reach of patients every day through investment, innovation and diversification, we’re enhancing our portfolio responsibly and creating strong shareholder returns.
A message from Hikma CEO Riad Mishlawi
Latest stories
Featured
Hikma delivers strong 2023 performance and a positive outlook for 2024
Press Release, Financial Results 22 February 2024
- Hikma celebrates 40 years of Hatch-Waxman drug savings Insight, Corporate 30 September 2024 Hikma celebrates 40 years of Hatch-Waxman drug savings
- Hikma: where our purpose inspires our people Insight, Corporate 23 September 2024 Hikma: where our purpose inspires our people
- Hikma launches Foscarnet Sodium Injection, in the US Press Release, Product 23 September 2024 Hikma launches Foscarnet Sodium Injection, in the US
- Hikma completes Xellia acquisition Press Release, Corporate 10 September 2024 Hikma completes Xellia acquisition
